Therefore, we explored the interplay between USP6NL, together with known EGFR status effectors of TMZ resistance, DNA damage repair, autophagy, and many mediators of GBM tumorigenesis, which may offer an alternative but efficient therapeutic strategy for targeting and eradicating otherwise resistant and recurrent phenotypes of aggressive GBM cells. This evidence concerns the gene USP6NL and glioblastoma.